GAL-001: Adaptive Phase II in Refractory Melanoma · Phase II
St. Brigid University Hospital · Dr. C. Nolan
consented 2026-07-08
AEs
2
Serious
1
Dropout signal
+0.1
☾ Luna — Elif Demir
granted
💬 4
⚠ 0 escalations
mood ø 3.0
meds 43%
📅 Symptom review call on 2026-08-19
Adverse events
severe
serious
under_review
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-11-11 (study day 469); relationship: not assessed; serious criteria: hospitalization
mild
assessed
Participant-reported via Luna chat: "I've had some nausea since yesterday evening". Solicited symptom report logged for the next visit review.
Data queries
conmed_dose
needs_human
Reported dose conflicts with pharmacy dispensing log; clinical interpretation needed (cross-check against deviation pattern "Subject received another investigational drug concurrently").